Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Free Cash Flow (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Free Cash Flow for 16 consecutive years, with $45.5 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 55.27% to $45.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.9 million through Dec 2025, down 48.64% year-over-year, with the annual reading at $48.9 million for FY2025, 48.64% down from the prior year.
  • Free Cash Flow hit $45.5 million in Q4 2025 for Ligand Pharmaceuticals, up from $13.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $101.6 million in Q4 2024 to a low of -$38.0 million in Q3 2024.
  • Historically, Free Cash Flow has averaged $19.2 million across 5 years, with a median of $15.9 million in 2022.
  • Biggest five-year swings in Free Cash Flow: soared 1878.41% in 2021 and later plummeted 588.57% in 2024.
  • Year by year, Free Cash Flow stood at $19.4 million in 2021, then surged by 164.13% to $51.3 million in 2022, then tumbled by 83.49% to $8.5 million in 2023, then skyrocketed by 1099.55% to $101.6 million in 2024, then plummeted by 55.27% to $45.5 million in 2025.
  • Business Quant data shows Free Cash Flow for LGNDZ at $45.5 million in Q4 2025, $13.5 million in Q3 2025, and $15.6 million in Q2 2025.